Mammaprint Blueprint, Updates from MINDACT 8.7 Year, & Applications in Neoadjuvant Therapy
Dr William Audeh, MD, Chief Medical Officer, Agendia, presents, "The MINDACT Trial and the 70-gene MammaPrint assay: Long Term Follow-Up Data in ER+ Breast Cancer". And, Dr. Lee Schwartzberg, MD, Chef Medical Officer, OneOncolog, presents, "Molecular Subtyping in Neoadjuvant Treatment."
▶︎
A Virtual Town Hall | Breast Cancer Care in the Time of COVID-19 | August 22, 2020
▶︎
Reduce the Risk of Recurrence with Nerlynx | Webinar on Therapeutic Decision-making
▶︎
Management of HER2 Low and HER2 Ultra Low - Greg Vidal, MD, PhD
▶︎
Improving Transdermal Fentanyl Prescribing
▶︎
Diversity, Inclusion, and Equity in Cancer Care | 2023 Best of Breast Conference
▶︎
Posture, Bone Density & Muscle: A Stanford Doctor Destroys Aging Myths Most People Believe
▶︎
What do tech pioneers think about the AI revolution? - The Engineers, BBC World Service
▶︎
The French Do Not Care About Work
▶︎
Personalized Medicine in Ovarian Cancer – Pier Paolo Claudio, MD
▶︎
Sen. Whitehouse to uncover connections between Trump, Russia, and Epstein.
▶︎
ELN 2025 Recommendations - What's Most Important for Latin America?
▶︎
Medical breakthroughs and health stories | 60 Minutes Marathon
▶︎
Spine Surgeon Drowns for 30 Minutes —Comes Back With a List
▶︎
Updates in Non Prostate Urogenital Cancers - Sandy Srinivas, MD
▶︎
Nutrition in Cancer Care – David James, ND
▶︎
Vitamin D Expert: The Fastest Way To Dementia & The Big Lie About Sunlight!
▶︎
AI has hacked the code of human civilization | Yuval Noah Harari
▶︎
Think Fast, Talk Smart: Communication Techniques
▶︎
NSCLC: Essential NGS Testing, Biomarkers, and Targeted Therapies - Shayma Kazmi, MD, RPh
▶︎